Published in Sci Rep on May 18, 2016
Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer. Cancer Sci (2017) 0.76
Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget (2016) 0.75
TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Diagn Pathol (2017) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res (2010) 43.51
Predicting deleterious amino acid substitutions. Genome Res (2001) 28.95
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 3.37
Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell (2007) 2.31
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol (2011) 2.02
The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol (2009) 1.90
p53 at a glance. J Cell Sci (2010) 1.88
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol (2012) 1.74
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2003) 1.49
p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol (1999) 1.45
p53 as a target for the treatment of cancer. Cancer Treat Rev (2014) 1.38
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol (2010) 1.28
Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer (2012) 1.27
Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol (2003) 1.22
Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res (1998) 1.22
Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol (2014) 1.21
Genomics: In search of rare human variants. Nature (2010) 1.20
Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med (2004) 1.08
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun (2015) 1.03
Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer (2010) 1.02
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther (2007) 1.01
Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. APMIS (2008) 0.99
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res (2012) 0.98
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther (2014) 0.89
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One (2012) 0.89
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol (2016) 0.88
p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer J (2001) 0.87
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer. Drug Discov Today (2015) 0.86
Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. Virchows Arch (2013) 0.84
Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis. Gynecol Oncol (2013) 0.76